Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 2,966

Document Document Title
WO/2018/124001A1
The present invention pertains to novel, exceptional low-molecular compounds that specifically antagonize the BMP signaling pathway, and because these compounds can be used to modulate cell growth, differentiation, proliferation, and apo...  
WO/2018/115591A1
Compounds of formula (I) wherein R1, R2,R3,R4,R5,R23,R24,L, A and Bare as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1(...  
WO/2018/084817A3
The present invention relates to a new crystalline form of an active agent, the preparation processes of said crystalline form, the pharmaceutical compounds containing said crystalline form and the use of said compounds in the treatment ...  
WO/2018/084817A2
The present invention relates to a new crystalline form of an active agent, the preparation processes of said crystalline form, the pharmaceutical compounds containing said crystalline form and the use of said compounds in the treatment ...  
WO/2018/083101A1
The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for p...  
WO/2018/083103A1
The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for p...  
WO/2018/055642A1
Provided herein is a process for synthesis of tiotropium bromide and a process for synthesis of scopine starting from a dimethyl tartarate compound. The synthetic sequence comprises a double Mannich reaction (Robinson-Schopf reaction).  
WO/2018/057596A1
A nasal spray composition and method for treating convulsive seizures, including epileptic seizures, and also autism behavioral events. In embodiments, the nasal spray composition contains delta-9-tetrahydrocannabinol and, optionally, te...  
WO/2018/031434A1
The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.  
WO/2018/009017A1
The present invention relates to 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical compositions containing the same, wherein the 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composit...  
WO/2017/216159A1
The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists.  
WO/2017/212425A1
The invention is directed to substituted piperidine derivatives. Specifically, the invention is directed to compounds according to Formula IIII: wherein A, B, X, Y, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, z2, z4, z5, and z6 are as define...  
WO/2017/201468A1
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or condit...  
WO/2017/197177A1
In various embodiments, compositions and methods are provided for treatment and/or prevention of amyloidogenic diseases. In certain embodiments, the methods entail administering an effective amount of compound C41 to a subject in need th...  
WO/2017/193951A1
Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases.  
WO/2017/189822A1
The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compos...  
WO/2017/179976A1
The invention relates to improved means and methods for N- dealkylation of alkylated amines. Provided is a method for the catalytic N- dealkylation of an N-alkylated amine substrate, comprising incubating said amine substrate in a suitab...  
WO/2017/165822A1
A compound, or a stereoisomer, pharmaceutically acceptable salt, or ester thereof, according to formula (III) or according to Table A, a pharmaceutical composition comprising said compound and at least one pharmaceutically acceptable add...  
WO/2017/165822A8
A compound, or a stereoisomer, pharmaceutically acceptable salt, or ester thereof, according to formula (III) or according to Table A, a pharmaceutical composition comprising said compound and at least one pharmaceutically acceptable add...  
WO/2017/148519A1
The invention relates to new heteroaryl derivatives of the formula wherein X 1 is selected from the group consisting of: N and CH; X 2 is selected from the group consisting of: N and CF; (whith the proviso that at least one of X1 and X2 ...  
WO/2017/144978A1
Proposed are a salt of tesofensine with optically-active acetylamino acids, and a method for producing same. The invention also relates to pharmaceutical compositions including a salt of tesofensine with optically-active acylamino acids ...  
WO/2017/141927A1
The present invention provides a compound represented by formula [I'], which has the effect of inhibiting an enzyme which produces 20-HETE, or a pharmaceutically acceptable salt thereof. (In formula [I']: the structure represented by for...  
WO/2017/138896A1
The present invention relates to a new crystalline form of an active agent, the processes for preparing this crystalline form, the pharmaceutical compositions comprising this crystalline form and the use of these compositions in the trea...  
WO/2017/123542A1
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: Formula (I) wherein R1 and ...  
WO/2017/102091A1
The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, ...  
WO/2017/090756A1
Provided is a compound represented by general formula (I) or a salt thereof. Also provided is an LSD1 inhibitor that contains this compound or a salt thereof as an active ingredient. Also provided is a pharmaceutical composition that con...  
WO/2017/069226A1
A compound represented by general formula [I] (in the formula, X represents N or the like, Y represents CH or the like, RA represents an optionally substituted cycloalkyl group or the like, R1 represents an alkyl group or the like, R2 re...  
WO/2017/055305A1
A series of substituted pyrazolo[1,5-a]pyrimidine and pyrazolo[1,5-a][1,3,5]- triazine derivatives of formula (I), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase ΙΙΙβ (ΡI4ΚΙΙΙβ) activity, are ben...  
WO/2017/028732A1
Disclosed are a preparation method of an orexin receptor antagonist compound 5-3, crystalline forms I-IV of the compound and preparation method thereof, and application of the crystalline forms in preparation of a drug treating a disease...  
WO/2017/025849A1
Compounds, tautomers and pharmaceutically acceptable salts of the compounds of Formula (Ia) are disclosed which are inhibitors of lnterleukin-1 receptor associated kinase (IRAK4). Methods of treatment, methods of synthesis, and intermedi...  
WO/2017/018409A1
Provided is a compound represented by formula (I). In formula (I), A- represents a halogen ion, a benzenesulfonate ion, an alkylsulfonate ion, or the like, X represents a halogeno group or the like, a is an integer of 0-4, Y represents a...  
WO/2017/004454A1
Disclosed herein are methods for use of R-chloroquine or clemizole or combinations of R- chloroquine and clemizole for the treatment of a subject in need thereof. Uses include methods of treating inflammatory' conditions, treating liver ...  
WO/2017/004454A8
Disclosed herein are methods for use of R-chloroquine or clemizole or combinations of R- chloroquine and clemizole for the treatment of a subject in need thereof. Uses include methods of treating inflammatory' conditions, treating liver ...  
WO/2017/004522A1
Provided herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDAC1, HDAC2, and HDAC3).  
WO/2016/203112A1
The present invention provides novel spiro[cyclobutane-1,3'-indolin]-2'- derivatives of formula (I) in which Cy R1, R2, R4, L and 'm' are have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The com...  
WO/2016/166604A1
Provided herein, inter alia, are compounds and methods for inhibiting PLK4 and for treating cancer in a subject in need thereof.  
WO/2016/082403A1
The invention relates to the field of compound synthesis, and mainly relates to a class of difluoro methylene piperidine carboxamide derivatives (I), a pharmaceutical composition containing same, and a preparation method and use thereof,...  
WO/2016/081679A1
The present invention relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, useful as IRAK inhibitors.  
WO/2016/050567A1
A compound of formula (I), wherein A and R1 are as defined in claim 1. Furthermore, the present invention relates to intermediates used to prepare compounds of formula (I), to methods of using them to combat and control insect, acarine, ...  
WO/2016/039048A1
The present invention provides a compound which is represented by formula (I-1) (wherein R4 represents a hydrogen atom, a C1-6 alkyl group or the like; Ar1 represents a C6-10 aryl group, a 3-6 membered heterocyclyl group or the like; A r...  
WO/2016/027780A1
A compound represented by formula (I), or a pharmaceutically acceptable salt thereof, acts as an FGFR inhibitor. [In the formula: A represents a C6-10 arylene group or the like that may have a substituent; J represents a C3-10 nitrogen-c...  
WO/2016/016692A1
A process for the production of atropine is provided. The process provides for a new, efficient and commercially feasible synthetic process for the preparation of atropine and atropine salts. In one aspect, a one pot process for the synt...  
WO/2015/199206A1
The present invention relates to a compound represented by formula (I), a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the compound or the salt. (In the formula, R1 represents a hydrogen atom or t...  
WO/2015/182724A1
 Provided are compounds that are useful as prophylactic or therapeutic agents for various diseases involving T-type calcium channels, such as hypertension, arrhythmia, pain and cancer, said compounds having antagonistic activity agains...  
WO/2015/162558A1
The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in the treatment of an ATX-dependent or ATX-med...  
WO/2015/131773A1
The present invention discloses a series of piperidine derivatives as orexin receptor antagonists and compositions thereof, and relates to the application thereof in preparing medications for the treatment of insomnia, chronic obstructiv...  
WO/2015/128440A1
A cocrystal of tiotropium bromide and lactose monohydrate is herein disclosed. In the cocrystal the components tiotropium bromide and lactose are preferably present in an almost stoichiometric ratio. Said cocrystal has a single endotherm...  
WO/2015/119099A1
The present invention obtains a compound indicated by formula (I) or a salt thereof. The present invention also obtains an agricultural and horticultural fungicide, a pest control agent, or a pesticide or miticide, that contains as the e...  
WO/2015/109451A1
The present invention mainly pertains to catalytic processes for the direct amination of 2, -bis(hydroxymethyl) tetrahydrofuran to obtain compounds containing the 8-oxa-3-azabicyclo (3.2.1) octane ring, in the presence of: a homogenous c...  
WO/2015/106058A1
The present invention provides compounds of Formula (II) for the treatment of cancer, rheumatoid arthritis and other diseases.  

Matches 1 - 50 out of 2,966